News room – What’s been happening

Sydney, Australia, Wednesday 5th February 2025: Cancer care provider GenesisCare Australia has released a report detailing its clinical research programs, noting its world-leading research into MRI-guided radiation therapy for prostate cancer patients.

The GenesisCare Annual Research Report shows that in 2024, GenesisCare’s MR-Linac team was the first in the world to deliver Stereotactic Ablative Radiation Therapy with a “sim-less” workflow through a research program harnessing MRI-guided radiation therapy tools. The report shows researchers developed a technical process that replaced the need for a pre-treatment simulation scan appointment with the aim of shortening a prostate cancer patient’s wait time for treatment by  reducing their number of visits and reducing associated patient anxiety^1,2.

Sonya McColl, GenesisCare’s Head of Research in Australia said doctors and research teams across medical oncology, radiation oncology, haematology, theranostics and precision medicine had made remarkable progress over the last year: “GenesisCare doubled the number of research investigators and more than tripled the number of published research articles in 2024,” said Ms McColl.

“The pioneering research of our MR-Linac team is considered world-leading^1,2 and not only helps to improve the treatment experience for patients but pushes the boundaries on what we can do with radiation therapy technology.”

The report noted broad trends in cancer research in Australia and highlighted four key areas: personalised medicine and biomarkers, theranostics and radiopharmaceuticals, growth, growth in early-phase trials, and combination therapies.

At the end of 2024, Genesiscare had 150 active research projects and 152 active research principal investigators across medical oncology, haematology, radiation oncology, theranostics and precision-medicine. The most studied tumour streams were prostate, breast and lung, with 3689 patients actively participating in a research project.

Download the GenesisCare Annual Research Report 2024.